September 20 - 23, 2014
Sheraton Philadelphia Downtown
Philadelphia, Pa., USA
Abstract submission deadline: Friday, August 8
Advance registration deadline: Monday, August 4
Continental Breakfast 7:00 a.m.-8:00 a.m.
Plenary Session 3: GenomicsSession Chairperson: Riccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, N.Y.8:00 a.m.-10:00 a.m.
Acute lymphoblastic leukemia: Recent insights from genomic profiling into pathophysiology and therapyCharles G. Mullighan, St. Jude Children’s Research Hospital, Memphis, TN
The evolutionary landscape of chronic lymphocytic leukemiaCatherine J. Wu, Dana-Farber Cancer Institute, Boston, Mass.
Pathogenetic and therapeutic insights from the genome of diffuse large B cell lymphomaRiccardo Dalla-Favera
AML genomics: An updateElaine R. Mardis, Washington University School of Medicine, St. Louis, Mo.
Break10:00 a.m.-10:30 a.m.
Concurrent Sessions 1-210:30 a.m.-12:30 p.m.
Concurrent Session 1: LeukemiaSession Chairperson: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Mass.
An oncogenic enhancer drives NOTCH1-induced leukemiaAdolfo Ferrando, Columbia University, New York, N.Y.
Integrating chemical and functional genomics for leukemia discoveryKimberly Stegmaier
Regulation of acute leukemia initiation and progression by long noncoding RNAsIannis Aifantis, New York University Langone Medical Center, New York, N.Y.
The histone demethylase Jmjd1c is required for MLL-AF9 leukemia initiating cell homeostasis through modulating Hoxa9-controlled transcription programNan Zhu, Memorial Sloan Kettering Cancer Center, New York, N.Y.*Investigating the use of tyrosine kinase inhibitors in Ph-like ALLKathryn G. Roberts, St. Jude Children’s Research Hospital, Memphis, Tenn.* Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemiaPanagiotis Ntziachristos, NYU Langone Medical Center, New York, N.Y.*
Concurrent Session 2: MyelomaSession Chairperson: Jonathan D. Licht, Northwestern University, Chicago, Ill. Targeting genetic heterogeneity in multiple myeloma through immune activationP. Lief Bergsagel, Mayo Clinic, Scottsdale, Ariz.
Aberrant histone methylation in multiple myelomaJonathan D. Licht, Northwestern University, Chicago, Ill.
Genomic-based treatment advances in Waldenstrom’s macroglobulinemiaSteven P. Treon, Dana-Farber Cancer Institute, Boston, Mass.
New insights into therapeutic targets in multiple myelomaKenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Mass.
Francesca Cottini, Dana-Farber Cancer Institute, Boston, Mass.*
Lunch12:30 p.m.-1:00 p.m.
Panel Discussion 2: Implementation of Clinical Genomics1:00 p.m.-2:30 p.m.Session Chairperson: Randy D. Gascoyne, BC Cancer Agency, Vancouver, B.C., Canada
Comprehensive clinical genomic profiling in hematolymphoid malignancies: An overviewVincent A. Miller, Foundation Medicine, Inc., Cambridge, Mass.Implementation of clinical genomics: Promise and challengesJohn D. Carpten, TGen, Phoenix, Ariz.How might next-generation sequencing penetrate clinical practice for lymphoid malignancies?Randy D. Gascoyne
Plenary Session 4: Cell Death PathwaysSession Chairperson: Suzanne Cory, The Walter and Eliza Hall Institute Of Medical Research, Melbourne, Australia2:30 p.m.-4:30 p.m.
Using mitochondria to guide leukemia therapyAnthony G. Letai, Dana-Farber Cancer Institute, Boston, Mass.
How cells survive: Single cell analysis reveals properties of nongenetic apoptosis resistance Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, Tenn.
Harnessing death for lifeSuzanne Cory
BCL-2 inhibition – An example of translational medicine – Update Gary B. Gordon, AbbVie Inc., North Chicago, Ill.
Break4:30 p.m.-5:00 p.m.
Panel Discussion 3: Clinical Research: Now and in the FutureSession Chairperson: James H. Doroshow, National Cancer Institute, Bethesda, Md.5:00 p.m.-6:30 p.m.
PanelistsPeter F. Lebowitz, Janssen Research & Development, Spring House, Pa.James H. DoroshowAnn Farrell, U.S. Department of Health and Human Services, Food and Drug Administration, Silver Spring, Md.
Dinner on Own6:30 p.m.-8:00 p.m.
Poster Session B and Reception8:00 p.m.-10:30 p.m.
*Short talks from proffered abstracts